Vedanta Biosciences Initiates Phase 2 Study for Lead Rationally-Defined Bacterial Consortium Product Candidate, VE303; First drug consisting of a rationally-defined bacterial consortium to advance to Phase 2 study; Previously announced Phase 1a/1b study d

Press/Media

Period17 Dec 2018

Media coverage

10

Media coverage